European journal of pharmacology · 2026
Ursocholic acid ameliorates hepatic steatosis via direct AMPK activation in preclinical models of MASLD.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Yong, Zeng Ze-Jie, Ye Anqi, Wang Weizhi, Huang Danxia, Hu Lijun, Li Shan, Li Jing, Zhang Lei
Аннотация
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major global health challenge lacking effective therapeutic agents. Ursocholic acid (UCA), a natural bile acid with established cholesterol-lowering properties, has not been evaluated for MASLD treatment.
OBJECTIVE: To investigate the therapeutic efficacy, mechanism of action, and pharmacokinetic profile of UCA in MASLD.
METHODS: Hepatoprotective effects were assessed in free fatty acid (FFA)-induced Huh7 cells and high-fat diet (HFD)-fed mice. RNA sequencing identified target pathways. Direct AMPK interaction was validated by molecular docking, molecular dynamics simulation, and cellular thermal shift assay. Pharmacokinetics was compared with ursodeoxycholic acid (UDCA).
RESULTS: UCA dose-dependently reduced hepatic lipid accumulation in vitro and in vivo. Transcriptomic analysis revealed AMPK signaling as the primary modulated pathway. Mechanistically, UCA directly bound to AMPK, promoted Thr172 phosphorylation, and downregulated lipogenic genes (SREBF1, LPIN1, FASN, SCD1), and these effects were abrogated by Compound C (AMPK inhibitor). Pharmacokinetically, UCA exhibited dose-proportional oral exposure (AUClast 1120-13,700 h ng/mL across 30-300 mg/kg) with a terminal half-life of 3.7-5.9 h, comparable to UDCA.
CONCLUSION: UCA is a direct AMPK agonist that ameliorates MASLD by suppressing the SREBF1/LPIN1 lipogenic axis, representing a promising natural therapeutic candidate.
OBJECTIVE: To investigate the therapeutic efficacy, mechanism of action, and pharmacokinetic profile of UCA in MASLD.
METHODS: Hepatoprotective effects were assessed in free fatty acid (FFA)-induced Huh7 cells and high-fat diet (HFD)-fed mice. RNA sequencing identified target pathways. Direct AMPK interaction was validated by molecular docking, molecular dynamics simulation, and cellular thermal shift assay. Pharmacokinetics was compared with ursodeoxycholic acid (UDCA).
RESULTS: UCA dose-dependently reduced hepatic lipid accumulation in vitro and in vivo. Transcriptomic analysis revealed AMPK signaling as the primary modulated pathway. Mechanistically, UCA directly bound to AMPK, promoted Thr172 phosphorylation, and downregulated lipogenic genes (SREBF1, LPIN1, FASN, SCD1), and these effects were abrogated by Compound C (AMPK inhibitor). Pharmacokinetically, UCA exhibited dose-proportional oral exposure (AUClast 1120-13,700 h ng/mL across 30-300 mg/kg) with a terminal half-life of 3.7-5.9 h, comparable to UDCA.
CONCLUSION: UCA is a direct AMPK agonist that ameliorates MASLD by suppressing the SREBF1/LPIN1 lipogenic axis, representing a promising natural therapeutic candidate.